Dr. Shoshana Shendelman, PhD is a scientist and entrepreneur, founder of several biotech companies, and a pioneer in developing drugs for rare and underserved diseases. Dr. Shendelman currently holds leadership roles in several private biotech companies, including Cyana Therapeutics, and is an advisor to both biotech and pharmaceutical companies.
Dr. Shendelman received a PhD from Columbia University Vagelos College of Physicians and Surgeons Integrated Program in Cellular, Molecular and Biophysical Studies, where she also completed her Master’s Degrees (both an MA and MSc). Dr. Shendelman’s neurobiological research at Columbia focused on molecular mechanisms driving neurogenerative diseases, and her doctoral thesis centered around molecular mechanisms of Parkinson’s Disease. She completed her Bachelor’s degree at Brandeis University, with a BA in biochemistry.
Dr. Shendelman holds numerous patents, and her research has been published in respected peer-reviewed publications, such as Orphanet Journal of Rare Diseases, The Journal of Clinical Pharmacology, Frontiers in Aging, JCI Insight, The Journal of Patient-Reported Outcomes (JPRO), and PLoS Biology.